Afatinib 40 MG

DRUG3 trials

Sponsors

German Cancer Research Center, H. Lee Moffitt Cancer Center and Research Institute, National University Hospital, Singapore

Conditions

Metastatic and Locally Advanced NRG1-rearranged MalignanciesNSCLCSquamous Cell Carcinoma

Phase 2

Afatinib in Advanced NRG1-Rearranged Malignancies

CompletedNCT04410653

German Cancer Research CenterMetastatic and Locally Advanced NRG1-rearranged Malignancies

Start: 2022-07-31End: 2023-10-04Updated: 2024-04-05

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Active, not recruitingNCT05070403

H. Lee Moffitt Cancer Center and Research InstituteSquamous Cell Carcinoma

Start: 2021-10-01End: 2028-03-01Updated: 2026-07-02

Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

RecruitingNCT06062823

National University Hospital, SingaporeNSCLC

Start: 2024-03-25End: 2026-12-31Target: 35Updated: 2025-07-24